Cargando…

Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis: Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms

Prebiotics may promote immune homeostasis and reduce sub-clinical inflammation in humans. This study investigated the effect of prebiotic galactooligosaccharide (GOS) supplementation in colonic inflammation. Seventeen patients with active ulcerative colitis (UC) consumed 2.8 g/d GOS for 6 weeks. At...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Bridgette, Eyice, Özge, Koumoutsos, Ioannis, Lomer, Miranda C., Irving, Peter M., Lindsay, James O., Whelan, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537576/
https://www.ncbi.nlm.nih.gov/pubmed/34684597
http://dx.doi.org/10.3390/nu13103598
_version_ 1784588293960105984
author Wilson, Bridgette
Eyice, Özge
Koumoutsos, Ioannis
Lomer, Miranda C.
Irving, Peter M.
Lindsay, James O.
Whelan, Kevin
author_facet Wilson, Bridgette
Eyice, Özge
Koumoutsos, Ioannis
Lomer, Miranda C.
Irving, Peter M.
Lindsay, James O.
Whelan, Kevin
author_sort Wilson, Bridgette
collection PubMed
description Prebiotics may promote immune homeostasis and reduce sub-clinical inflammation in humans. This study investigated the effect of prebiotic galactooligosaccharide (GOS) supplementation in colonic inflammation. Seventeen patients with active ulcerative colitis (UC) consumed 2.8 g/d GOS for 6 weeks. At baseline and 6 weeks, gene expression (microarray), fecal calprotectin (ELISA), microbiota (16S rRNA), short-chain fatty acids (SCFAs; gas-liquid chromatography), and clinical outcomes (simple clinical colitis activity index (SCCAI), gastrointestinal symptom rating scale (GSRS), and Bristol stool form scale (BSFS)) were measured. Following prebiotics, clinical scores (SCCAI), fecal calprotectin, SCFAs, and pH were unchanged. Five genes were upregulated and two downregulated. Normal stool proportion (BSFS) increased (49% vs. 70%, p = 0.024), and the incidence (46% vs. 23%, p = 0.016) and severity (0.7 vs. 0.5, p = 0.048) of loose stool (GSRS), along with urgency (SCCAI) scores (1.0 vs. 0.5, p = 0.011), were reduced. In patients with a baseline SCCAI ≤2, prebiotics increased the relative abundance of Bifidobacterium from 1.65% (1.97) to 3.99% (5.37) (p = 0.046) and Christensenellaceae from 0.13% (0.33) to 0.31% (0.76) (p = 0.043). Prebiotics did not lower clinical scores or inflammation but normalized stools. Bifidobacterium and Christensenellaceae proportions only increased in patients with less active diseases, indicating that the prebiotic effect may depend on disease activity. A controlled study is required to validate these observations.
format Online
Article
Text
id pubmed-8537576
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85375762021-10-24 Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis: Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms Wilson, Bridgette Eyice, Özge Koumoutsos, Ioannis Lomer, Miranda C. Irving, Peter M. Lindsay, James O. Whelan, Kevin Nutrients Article Prebiotics may promote immune homeostasis and reduce sub-clinical inflammation in humans. This study investigated the effect of prebiotic galactooligosaccharide (GOS) supplementation in colonic inflammation. Seventeen patients with active ulcerative colitis (UC) consumed 2.8 g/d GOS for 6 weeks. At baseline and 6 weeks, gene expression (microarray), fecal calprotectin (ELISA), microbiota (16S rRNA), short-chain fatty acids (SCFAs; gas-liquid chromatography), and clinical outcomes (simple clinical colitis activity index (SCCAI), gastrointestinal symptom rating scale (GSRS), and Bristol stool form scale (BSFS)) were measured. Following prebiotics, clinical scores (SCCAI), fecal calprotectin, SCFAs, and pH were unchanged. Five genes were upregulated and two downregulated. Normal stool proportion (BSFS) increased (49% vs. 70%, p = 0.024), and the incidence (46% vs. 23%, p = 0.016) and severity (0.7 vs. 0.5, p = 0.048) of loose stool (GSRS), along with urgency (SCCAI) scores (1.0 vs. 0.5, p = 0.011), were reduced. In patients with a baseline SCCAI ≤2, prebiotics increased the relative abundance of Bifidobacterium from 1.65% (1.97) to 3.99% (5.37) (p = 0.046) and Christensenellaceae from 0.13% (0.33) to 0.31% (0.76) (p = 0.043). Prebiotics did not lower clinical scores or inflammation but normalized stools. Bifidobacterium and Christensenellaceae proportions only increased in patients with less active diseases, indicating that the prebiotic effect may depend on disease activity. A controlled study is required to validate these observations. MDPI 2021-10-14 /pmc/articles/PMC8537576/ /pubmed/34684597 http://dx.doi.org/10.3390/nu13103598 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wilson, Bridgette
Eyice, Özge
Koumoutsos, Ioannis
Lomer, Miranda C.
Irving, Peter M.
Lindsay, James O.
Whelan, Kevin
Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis: Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms
title Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis: Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms
title_full Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis: Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms
title_fullStr Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis: Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms
title_full_unstemmed Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis: Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms
title_short Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis: Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms
title_sort prebiotic galactooligosaccharide supplementation in adults with ulcerative colitis: exploring the impact on peripheral blood gene expression, gut microbiota, and clinical symptoms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537576/
https://www.ncbi.nlm.nih.gov/pubmed/34684597
http://dx.doi.org/10.3390/nu13103598
work_keys_str_mv AT wilsonbridgette prebioticgalactooligosaccharidesupplementationinadultswithulcerativecolitisexploringtheimpactonperipheralbloodgeneexpressiongutmicrobiotaandclinicalsymptoms
AT eyiceozge prebioticgalactooligosaccharidesupplementationinadultswithulcerativecolitisexploringtheimpactonperipheralbloodgeneexpressiongutmicrobiotaandclinicalsymptoms
AT koumoutsosioannis prebioticgalactooligosaccharidesupplementationinadultswithulcerativecolitisexploringtheimpactonperipheralbloodgeneexpressiongutmicrobiotaandclinicalsymptoms
AT lomermirandac prebioticgalactooligosaccharidesupplementationinadultswithulcerativecolitisexploringtheimpactonperipheralbloodgeneexpressiongutmicrobiotaandclinicalsymptoms
AT irvingpeterm prebioticgalactooligosaccharidesupplementationinadultswithulcerativecolitisexploringtheimpactonperipheralbloodgeneexpressiongutmicrobiotaandclinicalsymptoms
AT lindsayjameso prebioticgalactooligosaccharidesupplementationinadultswithulcerativecolitisexploringtheimpactonperipheralbloodgeneexpressiongutmicrobiotaandclinicalsymptoms
AT whelankevin prebioticgalactooligosaccharidesupplementationinadultswithulcerativecolitisexploringtheimpactonperipheralbloodgeneexpressiongutmicrobiotaandclinicalsymptoms